Background: Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of
advanced-stage non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) …

Immune checkpoint inhibitors (ICI) have been validated as an effective new treatment
strategy in several tumoral types including lung cancer. This remarkable shift in the …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Simple Summary Immuno-oncology has redefined the treatment of lung cancer, with the
ultimate goal being the reactivation of the anti-tumor immune response. This has led to the …

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been
shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy …

The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major
changes to the therapeutic landscape of lung cancer. Improvements in overall survival …

Background Lung cancer is the leading cause of cancer‐related deaths worldwide and the
prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or …

Background Non‐small cell lung cancer (NSCLC) is the predominant type of lung cancer,
and most clinically curable patients are diagnosed with locally advanced disease. Although …

Over the last decade, we have witnessed a paradigm shift in cancer treatment, with the
advent of novel therapeutic approaches that target or manipulate the immune system, also …